The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

Improving Global Access to Life-Changing Therapeutics... Following the successful Boston and London meetings, the ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Netherlands biotech Azafaros is poised to start phase 3 trials of its lead drug for a trio of rare lysosomal storage ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

President Donald Trump has signed an executive order that he claims will cut prescription drug prices supplied to the US to ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...